Characteristics of Pseudomonas aeruginosa isolates from intensive care unit

Central European Journal of Medicine

Volumn 4, Issue 2, 2009, Pages 156-163

  Ozer, Burcin ^a   Tatman Otkun, Muserref ^b   Memis, Dilek ^b   Otkun, Metin ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY   (Turkey)

Author keywords

Chromosomal beta lactamase; Intensive care unit; Metallo beta lactamase; Pseudomonas aeruginosa; Pulsed field gel electrophoresis; Serotypes

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; HOSPITAL INFECTION; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; MEDICAL STAFF; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEROTYPE;

EID: 70349564832     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-008-0090-2     Document Type: Article

References (27)

1. Kiska D.L., Gilligan P.H., Pseudomonas, In: Muray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (Eds.), Manual of Clinical Microbiology. 8th ed., ASM Pres, Washington, 2003, 1970-1980
2. Pollack M., Pseudomonas aeruginosa, In: Mandell GL, Bennett JE, Dolin R (Eds), Principles and Practice of Infectious Diseases. 4th ed., Churchill Livingstone, New York, 1995, 1980-2003
3. R.E.W. Hancock 1998 Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria Clin. Infect. Dis. 27 93 99 10.1086/514909
4. Gaynes R.P., Horan T.C., Surveillance of nosocomial infections, In: Mayhall CG (ed), Hospital Epidemiology and Infection Control.1st ed. Lippincott Willams and Wilkins, Philadelphia, 1996, 1017-1037
5. L.J. Strausbaugh D.L. Sewell R.C. Tjoelker T. Heitzman T. Webster T. Ward, et al. 1996 Comparison of three methods for recovery of yeasts from hands of health-care workers J. Clin. Microbiol. 34 471 473 8789043 1:STN:280:BymA1c7gtlQ%3D
6. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk Susceptibility Tests, CLSI document M2-A9, (2006)
7. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Susceptibility Testing, CLSI document M100-S16 (2006)
8. J.A. Karlowsky D.C. Draghi M.E. Jones C. Thornsberry I.R. Friedland D.F. Sahm 2003 Surveillance for antimicrobial susceptibility among clinical iosalates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2002 Antimicrob. Agents. Chemother. 47 1681 1688 12709340 10.1128/AAC.47.5.1681-1688.2003 1:CAS:528: DC%2BD3sXjslGhtbk%3D (Pubitemid 36548554)
9. F. Akata M. Otkun B. Teker O. Karabay A. Öǧütlü M. Tuǧrul, et al. 1997 Frequencies of extended spectrum and chromosomal beta-lactamases in nosocomial gram-negative bacteria Turkish Journal of Infection 11 256 259
10. S. Goto A. Tsuji T. Oguri I. Kobayashi M. Nishida E. Yabuuchi 1999 Present situation of serotyping of Pseudomonas aeruginosa in Japan and correlation among three kinds of commercially available serotyping kits J. Infect. Chemother. 5 201 205 11810517 10.1007/s101560050035
11. J. Hernàndez M.A. Ferrús M. Hernàndez R.J. Owen 1997 Arbitrary primed PCR fingerprinting and serotyping of clinical Pseudomonas aeruginosa strains FEMS Immun. Med. Microbiol. 17 37 47
12. H. Speijer P.H.M. Savelkoul M.J. Bonten E.E. Stobberingh J.H.T. Tjhie 1999 Application of different genotyping methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit J. Clin. Microbiol. 37 3654 3661 10523569 1:STN:280:DyaK1MvlsVylsQ%3D%3D
13. F.C. Tenover R.D. Arbeit R.V. Goering P.A. Mickelsen B.E. Murray D.H. Persing, et al. 1995 Interpreting Chromosomal DNA restriction patterns produced by Pulsed-Field Gel Electrophoresis: Criteria for bacterial strain typing J. Clin. Microbiol. 33 2233 2239 7494007 1:CAS:528:DyaK2MXoslSisLc%3D
14. C.J. Henwood D.M. Livermore D. James M. Warner the Pseudomonas study group 2001 Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disk susceptibility test J. Antimicrob. Chemother. 47 789 799 11389111 10.1093/jac/47.6.789 1:CAS:528:DC%2BD3MXksFCiu78%3D
15. Swenson J.M., Hindler J.A., Peterson R.L., Antimicrobial agents and susceptibility testing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (Eds.), Manual of Clinical Microbiology. 8th ed. ASM Pres, Washington, 2003, 1178-1195
16. L.M.C. Hall D. LIvermore D. Gur M. Akova H.E. AkalIn 1993 OXA-11, an extended-spectrum variant of OXA-10 (PSE-2), beta-lactamase from Pseudomonas aeruginosa Antimicrob. Agents. Chemother. 37 1637 1644 8215276 1:CAS:528:DyaK2cXktlOj
17. T.R. Walsh M.A. Toleman L. Poirel P. Nordmann 2005 Metallo-Lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18 306 325 15831827 10.1128/CMR.18.2.306-325.2005 1:CAS:528:DC%2BD2MXksVymtb0%3D (Pubitemid 40548296)
18. S. Pournaras M. Maniati E. Petinaki S. Tzouvelekis A. Tsakris N.J. Legakis, et al. 2003 Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4 J. Antimicrob. Chemother. 51 1409 1414 12716773 10.1093/jac/dkg239 1:CAS:528:DC%2BD3sXktVCgt7g%3D (Pubitemid 36748930)
19. H. Vahaboglu F. Coskunkan O. Tansel R. Oztürk N. Sahin I. Koksal, et al. 2001 Clinical importance of extended-spectrum beta-lactamase (PER-1 type)- producing Acinetobacter spp, and Pseudomonas aeruginosa strains J. Med. Microbiol. 50 642 645 11444775 1:CAS:528:DC%2BD3MXlt1OgsLg%3D
20. K. Lee W.G. Lee Y. Uh G.Y. Ha J. Cho Y. Chong, et al. 2003 VIM and IMP-type metallo-beta-lactamaseproducing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals Emerg. Infect. Dis. 9 868 871 12890331 1:CAS:528: DC%2BD3sXmtVCksb8%3D
21. A.C. Gales R.N. Jones J. Turnidge R. Rennie R. Ramphal 2001 Characterization of Pseudomonas aeruginosa isolates: occurance rates, antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin. Infect. Dis. 32 Suppl2 146 155 10.1086/320186
22. R.M. Shawar D.L. Macleod R.L. Garber J.L. Burns J.R. Stapp C.R. Clausen, et al. 1999 Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob. Agents. Chemother. 43 2877 2880 10582875 1:CAS:528:DyaK1MXnvVCqsb4%3D
23. D.J. Wolter E. Smith-Moland R.V. Goering N.D. Hanson P.D. Lister 2004 Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital Diag. Microbiol. Infec. Dis. 50 43 50 10.1016/j.diagmicrobio.2004.05.004 1:CAS:528:DC%2BD2cXnslGjtLc%3D (Pubitemid 39360261)
24. The International Pseudomonas aeruginosa Typing Study Group 1994 A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominantly from patients with cystic fibrosis J. Infect. Dis. 169 134 142
25. P.T. Tassios V. Gennimata L. Spaliara-Kalogeropoulou D. Kairis C. Koutsia A.C. Vatopoulos, et al. 1997 Multiresistant Pseudomonas aeruginosa serogroup O11 outbreak in an intensive care unit Clin. Microbiol. Infect. 3 621 628 11864203 10.1111/j.1469-0691.1997.tb00468.x
26. T.A. Vale M.A. Gaston T.L. Pitt 1988 Subdivision of seroypes of Pseudomonas aeruginosa with monoclonal antibodies J. Clin. Microbiol. 26 1779 1782 3141466 1:STN:280:DyaL1M%2FjsVOktw%3D%3D
27. Y.L. Wu E.M. Scott A.L.W. Po V.N. Tariq 1999 Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa J. Antimicrob. Chemother. 44 389 392 10511408 10.1093/jac/44.3.389 1:CAS:528:DyaK1MXmt1aqtL8%3D (Pubitemid 29425692)